Lilly’s Cyramza Wins Slim Nod, But Steba’s Tookad Falls Hard At US FDA Panel
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.
You may also be interested in...
Keeping Track: Tecentriq, Cyramza Celebrate ASCO With New Indications; Brilinta Moves Earlier In Coronary Artery Disease
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Lilly included progression-free survival 2 as an exploratory endpoint in RELAY on the advice of the European Medicines Agency and says study results show continuing benefit from first-line ramucirumab even after progression; FDA says endpoint is not valid for regulatory purposes and is subject to confounding.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.